Evaluation of Safety and Efficacy of L19TNF and Lomustine in Patients with Glioblastoma at First Progression

The primary objective of this study is to evaluate the **safety** and **efficacy** of the tumor-targeting human antibody-cytokine fusion protein L19TNF in combination with lomustine in patients with **glioblastoma** at first progression. This is clinically relevant as glioblastoma is an aggressive brain tumor with limited treatment options, and assessing the potential benefits and risks of this novel therapeutic approach could provide valuable insights into improving patient outcomes.

The clinical trial involves a total of **63 participants** diagnosed with **glioblastoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified beyond their diagnosis. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The sponsor has not provided specific information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the safety and efficacy of a tumor-targeting human antibody-cytokine fusion protein, L19TNF, in combination with **lomustine** for patients with **glioblastoma** at first progression. The study employs a randomized, double-blind, controlled trial design to ensure the reliability and validity of the results. The trial is expected to commence recruitment on February 1, 2023, and is projected to conclude by February 28, 2027, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor safety, efficacy, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the completion of the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement will vary depending on individual response to treatment and progression of the disease. Conditions that may lead to early termination from the study include significant adverse reactions, disease progression beyond predefined criteria, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements to ensure participant safety and data integrity throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is scheduled to commence recruitment on February 1, 2023, and is estimated to conclude by February 28, 2027. The trial is categorized under phase 9, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation.